Computationally optimized antigens to overcome influenza viral diversity

Expert Review of Vaccines

Volumn 11, Issue 3, 2012, Pages 267-269

  Giles, Brendan M ^a   Ross, Ted M ^b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

H5N1; influenza; vaccines; viral diversity

Indexed keywords

INFLUENZA VACCINE;

CLADISTICS; CROSS PROTECTION; CROSS REACTION; DRUG FORMULATION; EDITORIAL; HUMAN; IMMUNE RESPONSE; INFLUENZA VIRUS A H5N1; NONHUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS REPLICATION;

ANIMALS; ANTIGENS, VIRAL; COMPUTER-AIDED DESIGN; CROSS PROTECTION; CROSS REACTIONS; DESIGNER DRUGS; GENETIC VARIATION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 84859090933     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.3     Document Type: Editorial

References (24)

1. Subbarao K, Luke C. H5N1 viruses and vaccines. PLoS Pathogens 3(3), e40 (2007).
2. Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19(13-14), 1732-1737 (2001).
3. Stephenson I, Bugarini R, Nicholson K et al. Cross reactivity tohighly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59 adjuvanted influenza A/Duck/ Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191(8), 1210-1215 (2005).
4. Cinatl J Jr, Michaelis M, Doerr H. The threat of avian influenza A (H5N1). Part IV: development of vaccines. Med. Microb. Immunol. 196(4), 213-225 (2007).
5. Finnefrock AC, Liu X, Opalka DW et al. HIV Type 1vaccines for worldwide use: predicting in-clade and cross-clade breadth of immune responses. AIDS Res. Hum. Retroviruses 23(10), 1283-1292 (2007).
6. Kesturu GS, Colleton BA, Liu Y et al. Minimization of genetic distances by the consensus, ancestral, and center-of-tree (COT) sequences for HIV-1 variants within an infected individual and the design of reagents to test immune reactivity. Virology 348(2), 437-448 (2006).
7. Gao F, Liao H-X, Hahn BH et al. Centralized HIV-1 envelope immunogens and neutralizing antibodies. Curr. HIV Res. 5(6), 572-577 (2007).
8. Malm M, Rollman E, Ustav M et al. Cross-clade protection induced byhuman immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. Viral Immunol. 18(4), 678-688 (2005).
9. Laddy DJ, Yan J, Khan AS et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J. Virol. 83(9), 4624-4630 (2009).
10. Giles BM, Bissel SJ, DeAlmeida DR et al. Antibody breadth and protective efficacy is increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin base H5N1 VLP vaccines. Clin. Vaccine Immunol. doi:10.1128/CVI.05533-11 (2011) (Epub ahead of print).
11. Giles BM, Crevar CJ, Carter DM et al. Computationally-optimized hemagglutinin expressed ona virus-like particle vaccine elicits broadly-reactive antibodies that protect non-human primates from H5N1 clade 2 influenza infection. J. Infect. Dis. (2011) (In Press).
12. Gao F, Weaver EA, Lu Z et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus Type 1 group M consensus envelope glycoprotein. J. Virol. 79(2), 1154-1163 (2005).
13. Hamano T, Sawanpanyalert P, Yanai H et al. Determination of HIV Type 1 CRF01-AE gag p17 and env-V3 consensus sequences for HIV/AIDS vaccine design. AIDS Res. Hum. Retroviruses 20(3), 337-340 (2004).
14. Krohn K, Stanescu I, Blazevic V et al. A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies. Microbe. Infect. 7(14), 1405-1413 (2005).
15. Mwau M, Cebere I, Sutton J et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85(4), 911-919 (2004).
16. Tompkins SM, Zhao Z-S, Lo C-Y et al. Matrix protein 2vaccination and protection against influenza viruses, including subtype H5N1. Emer. Infect. Dis. 13(3), 426-435 (2007).
17. Laddy DJ, Yan J, Corbitt N et al. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 25(16), 2984-2989 (2007).
18. Laddy DJ, Yan J, Kutzler M et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE 3(6), e2517 (2008).
19. Giles BM, Ross TM. Development of acomputationally optimized broadly reactive (COBRA) hemagglutinin for elicitation of protective antibodies against multiple clades of H5N1. Vaccine 29, 3043-3054 (2011).
20. Horimoto T, Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat. Rev. Microbiol. 3(8), 591-600 (2005).
21. Taubenberger JK, Kash JC. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe 7(6), 440-451 (2010).
22. Lipatov AS, Govorkova EA, Webby RJ et al. Influenza: emergence and control. J. Virol. 78(17), 8951-8959 (2004).
23. World Health Organization. Avian influenza: assessing the pandemic threat. 2005. www.who.int/csr/disease/influenza/WHO-CDS-2005-29/en/index.html
24. World Health Organization. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as human vaccines. February 27, 2008. www.who.int/csr/disease/avian-influenza/guidelines/ H5VaccineVirusUpdate20080214.pdf.